HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 adalimumab study

BACKGROUND: Determining treatment response for patients with hidradenitis suppurativa (HS) can be challenging due to limitations of current disease activity evaluations. OBJECTIVE: Evaluate the novel, validated endpoint, Hidradenitis Suppurativa Clinical Response (HiSCR) and its utility as an outcom...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimball, A.B., Sobell, J.M., Zouboulis, C.C., Gu, Y., Williams, D.A., Sundaram, M., Teixeira, H.D., Jemec, G.B.E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Original Articles and Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034809/
https://www.ncbi.nlm.nih.gov/pubmed/26201313
http://dx.doi.org/10.1111/jdv.13216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034809/
https://www.ncbi.nlm.nih.gov/pubmed/26201313
http://dx.doi.org/10.1111/jdv.13216

Ejemplares similares